Last reviewed · How we verify
Neis-Vac-C
Neis-Vac-C is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.
Neis-Vac-C is a meningococcal serogroup C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.
Neis-Vac-C is a vaccine that has been studied for its effectiveness against Neisseria Meningitidis and Haemophilus Influenzae Type b. It is administered as part of a full vaccination course that includes Menitorix, a pneumococcal conjugate vaccine.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Neis-Vac-C |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsular material from N. meningitidis serogroup C conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent B-cell responses. This generates both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by serogroup C strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)
- Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neis-Vac-C CI brief — competitive landscape report
- Neis-Vac-C updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Neis-Vac-C
What is Neis-Vac-C?
How does Neis-Vac-C work?
What is Neis-Vac-C used for?
Who makes Neis-Vac-C?
What drug class is Neis-Vac-C in?
What development phase is Neis-Vac-C in?
What are the side effects of Neis-Vac-C?
What does Neis-Vac-C target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroup C polysaccharide capsule
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing